U.S. Markets closed
  • S&P 500

    4,246.59
    -8.56 (-0.20%)
     
  • Dow 30

    34,299.33
    -94.42 (-0.27%)
     
  • Nasdaq

    14,072.86
    -101.29 (-0.71%)
     
  • Russell 2000

    2,320.07
    -6.07 (-0.26%)
     
  • Crude Oil

    72.46
    +0.34 (+0.47%)
     
  • Gold

    1,859.00
    +2.60 (+0.14%)
     
  • Silver

    27.80
    +0.11 (+0.39%)
     
  • EUR/USD

    1.2129
    -0.0004 (-0.0364%)
     
  • 10-Yr Bond

    1.4990
    -0.0020 (-0.13%)
     
  • Vix

    17.02
    +0.63 (+3.84%)
     
  • GBP/USD

    1.4081
    -0.0001 (-0.0084%)
     
  • USD/JPY

    110.0800
    +0.0460 (+0.0418%)
     
  • BTC-USD

    40,240.42
    -295.68 (-0.73%)
     
  • CMC Crypto 200

    995.03
    -15.57 (-1.54%)
     
  • FTSE 100

    7,172.48
    +25.80 (+0.36%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Why Aurinia Pharmaceuticals Stock Is Crashing Today

·2 min read
Why Aurinia Pharmaceuticals Stock Is Crashing Today
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH), an early commercial-stage biotech, are down by 17% in after-hours trading Thursday afternoon. The biotech's stock is cratering in response to the company's 2021 first-quarter earnings report released after the closing bell today. Investors appear to be backing away from Aurinia today for one simple reason: Sales of the biotech's newly approved lupus nephritis medication Lupkynis (aka voclosporin) failed to break even $1 million during the first quarter of 2021.